Generic Name and Brand Name Generic Name:

Pregabalin

Classifica-tion

Action

Dosage

Indication

Contraindication

Side Effects

Nursing Responsibility

anticonvulsants Binds with high affinity to the alpha2delta site( an auxiliary subunit of voltagegated calcium channels) in CNS tissues.

Brand names: Lyrica

Given orally with or without food. When discontinuing LYRICA, taper gradually over a minimum of 1 week.

Treatment of neuropathic pain in adults. As adjunctive therapy of partial seizures with or without secondarily generalization The maximum in patient recommended aged 12 and dose of above. LYRICA is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Begin dosing at 50 mg three

Hypersensitivity to the active substance or to any of the excipients. Lactation.

ASSESSMENT Neutropenia, -obtain pt history appetite before medication. increase, -monitor anorexia, hypersensitivity of hypoglycaemia. pt to drug and Euphoric other component. mood, -monitor for confusion, decreased platelet libido count. decreased, -monitor for irritability. elevated creatine Nervous kinase. system disorder i.e. NSG DIAGNOSES: dizziness, -risk for traumatic ataxia, injury related to disturbance in seizure disorder. attention, -risk for impaired memory skin integrity impairment, related to tremor, dermatologic dysarthria. Eye reaction. disorders i.e. -knowledge-deficit blurred vision, related to drug diplopia, visual therapy.

times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Because LYRICA is eliminated primarily by renal excretion, adjust the dose in patients with reduced renal function.

disturbances, dry eye, eye swelling, visual acuity reduced, eye pain, asthenopia, lacrimation increased. Vertigo, hyperacusis, tachycardia, AV block 1st degree, sinus tachycardia. GIT disorders i.e. dry mouth, constipation, vomiting and flatulence. General disorders i.e. fatigue, feeling drunk, peripheral edema, gait abnormality, weight increase.

PLANNING: -give by oral administration, with or without food. -store at temperature not exceeding 25 Celsius. IMPLEMENTATION:
- Instruct patient to notify prescriber if she has changes in vision or unexplained muscle pain, tenderness, or weakness, especially if these muscle symptoms are accompanied by malaise or fever. - Alert patient that drug may cause edema and weight gain. -Inform male patient who plans to father a child that drug could impair his fertility.

- Instruct diabetic patients to inspect their skin while taking pregabalin. EVALUATION: -pt does not exp. Seizure. -decreased in severity of seizures. -pt does not develop drug induced adverse reactions. -pt and family state understanding of drug therapy.